Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial
暂无分享,去创建一个
H. Haller | M. Meier | C. Farsang | J. Menne | C. Sieder | S. Klebs | R. Handrock | László Deák
[1] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[2] G. Bakris,et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. , 2007, Kidney international.
[3] K. Tuttle. Albuminuria reduction: the holy grail for kidney protection. , 2007, Kidney international.
[4] H. Parving,et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus , 2007, Journal of hypertension.
[5] M. Weir. Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[6] G. Fernández-Juárez,et al. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. , 2006, Journal of the American Society of Nephrology : JASN.
[7] O. Gedik,et al. Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes , 2006, Advances in therapy.
[8] R. Henning,et al. Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage , 2006, Journal of Cardiovascular Pharmacology.
[9] Y. Altuntas,et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. , 2006, Diabetes research and clinical practice.
[10] H. Parving,et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.
[11] N. Wareham,et al. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? , 2005, Current opinion in nephrology and hypertension.
[12] M. Nieminen,et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.
[13] Hans L. Hillege,et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.
[14] R. MacInnis,et al. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[15] H. Morita,et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.
[16] H. Morita,et al. RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.
[17] G. Leoncini,et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. , 2002, Journal of the American Society of Nephrology : JASN.
[18] G. Viberti,et al. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.
[19] O. Gedik,et al. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study , 2001, Acta Diabetologica.
[20] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[21] D. Grobbee,et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity , 2001, Journal of internal medicine.
[22] M. Cooper,et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.
[23] J. García-Puig,et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. , 1996, Journal of human hypertension.
[24] R. Garrick. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease , 2009 .
[25] G. Kimura,et al. [Microalbuminuria in hypertension]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.